

Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022

<https://marketpublishers.com/r/P57CA921E30EN.html>

Date: October 2012

Pages: 182

Price: US\$ 2,401.00 (Single User License)

ID: P57CA921E30EN

Abstracts

New study shows you commercial prospects for leading biosimilar producers

What does the future hold for top companies in the biosimilars industry? Visiongain's new report shows you their prospects to 2022. You find financial data, trends, opportunities and revenue potentials.

We analyse 25 leading developers and producers of biosimilars (follow-on biologics). Our analyses help you see the future of that industry and market. See how sales can increase.

Discover forecasts and discussions to help you stay ahead in knowledge

You discover revenue forecasts to 2022 for eight companies and the industry, growth rates, ranking and market shares. Also, you see qualitative analysis (inc. SWOT), news, business outlooks and research and development (R&D). You receive 43 charts and 92 tables.

Our investigation lets you find lucrative areas of that industry. You see the potential of leading biosimilar producers, assessing their technologies and commercial outlooks. Their activities hold promise for the future. We predict high market growth from 2012 to 2022.

You can gain in knowledge of protein-based drugs, benefiting your research and analyses. See the next stage for biologicals - the influence of follow-on products.

The following sections highlight what you find in our report.

The leading company - you see prospects to 2022 for Sandoz

Will Sandoz remain the market leader? See information on its activities in 2012, looking ahead.

You find discussion and analysis of its product portfolio:

Omnitrope (somatropin)

Binocrit (epoetin alpha)

Zarzio (filgrastim).

Also you investigate Sandoz's R&D pipeline, its commercial challenges from 2012 and a forecast of its biosimilars revenue to 2022. Next, we cover many other companies.

See prospects for other leading biosimilar manufacturers based in developed countries

Our report gives you profiles and analyses for many other companies based in developed regions - these biopharma specialists:

Teva Pharmaceutical Industries

Hospira

Stada Arzneimittel

Medice Arzneimittel Pütter

JCR Pharmaceuticals.

There you examine products, progress, sales breakdowns, R&D pipelines and outlooks, including biosimilar revenue potentials to 2022. You see what's happening.

We show components of the industry. You assess strengths, weaknesses, opportunities and threats (SWOT factors). Also, you find linked organisations, including alliances and

licensing. You see market entry strategy too, and mergers and acquisitions (M&A activity).

Also we analyse competition, featuring these biomedical companies as well:

Watson

Mylan

Pfizer

Boehringer Ingelheim

Mochida Pharmaceutical

Nippon Kayaku

Nichi-Iko Pharmaceutical.

Next, our investigation assesses prominent companies in developing regions.

What are the outlooks for Chinese, Indian and Latin American producers?

China is the largest national biosimilars market. Our report shows you developments and prospects for Chinese biotech manufacturers working with those medicines:

3SBio

Beijing SL Pharmaceutical

GeneScience Pharmaceuticals (GenSci)

Shanghai Fosun Pharmaceutical

Tonghua Dongbao.

Also, you see profiles of companies in India:

Biocon

Dr. Reddy's Laboratories

Intas Biopharmaceuticals

Reliance Life Sciences

Wockhardt

Zydus Cadila.

Our study also assesses firms based in Latin America:

Probiomed

Biosidus

Amega Biotech

Aché.

You find outlooks to 2022 for leading participants in developing countries. We discuss other contenders (e.g. Ranbaxy), as well as R&D and commercial alliances.

The study covers other emerging regions too.

What are the prospects for companies based in the CEE area and South Korea?

You see outlooks for Central and Eastern European (CEE, inc. Russia) and South Korean companies:

Bioton

Pharmstandard

LG Life Sciences

Dong-A.

We assess other competitors too. Also, see acquisitions and alliances. In our study you find R&D and other issues affecting future sales for that industry.

You also find revenue predictions for the overall biosimilars industry to 2022

Our report forecasts and discusses biosimilar therapies by overall world market and product category. You see individual forecasted revenues and growth rates to 2022 for six world-level submarkets (therapeutic classes):

Monoclonal antibodies (mAbs) and fusion proteins

Insulins

Interferons

Growth hormones

Erythropoietins (EPO)

Granulocyte colony-stimulating factor (G-CSF, filgrastim)

Other relevant types of biological medicine (e.g. recombinant blood factors, follicle stimulating hormone and interleukins, with forecasting as a single group).

In 2011 total biosimilar revenues reached \$1.68bn. We predict high growth there to 2022. See the sales potential of the world market and find its most promising segments.

This decade many opportunities in biosimilars will occur. Pharma corporations and specialty healthcare operations - especially leading generics specialists - will develop and prosper.

Eight ways Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022 helps you

To sum up, then, our report gives you the following knowledge on those biological agents:

Profiles of 25 leading companies - discover product ranges, recent results, sales distributions, strategies, competition and outlooks

Prospects for companies in the Americas, Europe and Asia - assess top players worldwide, seeing opportunities, production data, challenges and potentials

Forecasted revenues to 2022 for 8 companies - see predicted financial results for prominent firms

Potential revenues to 2022 for the overall world biosimilars market and 6 product categories (therapeutic classes) - find the industry's sales outlook

Review of R&D pipelines - investigate developmental trends and progress

Investigation of competition and opportunities influencing sales

Discussion of what stimulates and restrains companies, the industry and the market

Prospects for established organisations and those seeking to enter the sector.

That work gives you quantitative and qualitative analysis with independent predictions. You receive information found only in our study.

There you find business intelligence to help you understand the next phase of the biologics industry and market. You see where prospects are lucrative and revenue growth is likely.

With our report you are less likely to fall behind in knowledge. Discover how our work could benefit your research and analyses, saving you time too.

You see prospects for top biosimilar drug producers by ordering now

Visiongain's study is for everyone needing analysis of the industry and market for biopharmaceuticals. You find data, trends and predictions. Please order our report now.

Contents

1. EXECUTIVE SUMMARY

- 1.1 Top Biosimilar Drug Manufacturers: Overview of Findings
- 1.2 Report Contents
- 1.3 Report Methods
- 1.4 Scope and Format of Report

2. WORLD BIOSIMILAR DRUGS MARKET 2012-2022: AN INTRODUCTION

- 2.1 Introduction to Biologics and Biosimilars
 - 2.1.1 Classes of Biologic and Biosimilar Drugs
- 2.2 The World Biosimilar Drugs Market 2012-2022
 - 2.2.2 The World Biosimilar Drugs Market Forecast 2012-2022
- 2.3 What Will Drive Biosimilar Drugs Market Growth Between 2012 and 2022?
- 2.4 Restraints Exist for the Biosimilar Drugs Market Between 2012 and 2022
- 2.5 Leading Companies in the Biosimilars Market 2011
 - 2.5.1 How Will the Top 25 Ranking Change Between 2012 and 2022?

3. TOP BIOSIMILAR MANUFACTURERS IN DEVELOPED MARKETS 2012-2022

- 3.1 Sandoz: The Biosimilars Market Leader 2012
 - 3.1.1 Three Biosimilars Marketed Worldwide
 - 3.1.1.1 Omnitrope (Somatropin): A Global Biosimilar Brand
 - 3.1.1.2 Binocrit (Epoetin Alpha)
 - 3.1.1.3 Zarzio (Filgrastim)
 - 3.1.2 Revenue Growth 2008-2011
 - 3.1.3 Biosimilars Pipeline 2012
 - 3.1.3.1 Biosimilar Rituximab: First to Market in the EU?
 - 3.1.4 Sandoz: Biosimilars Market Outlook
 - 3.1.4.1 Sandoz: Biosimilars SWOT Analysis 2012-2022
 - 3.1.4.2 Will Sandoz be the Biosimilars Market Leader in 2022?
- 3.2 Teva
 - 3.2.1 Biosimilar Product Portfolio
 - 3.2.1.1 Tevagastim (Filgrastim)
 - 3.2.1.2 Eporatio (Epoetin Theta)
 - 3.2.1.3 Teva Acquires Ratiopharm
 - 3.2.1.4 Expansion in Eastern Europe: Teva Acquires Sicor Biotech

- 3.2.2 Oncology Biosimilars Drive Revenue Growth 2009-2011
- 3.2.3 Teva to Launch Biosimilars in Japan
- 3.2.4 Biosimilars Pipeline 2012
 - 3.2.4.1 Teva Collaborates with Lonza to Develop Biosimilar Rituximab
 - 3.2.4.2 Teva Will be First to Launch Biosimilar Filgrastim in the US
- 3.2.5 Teva: Biosimilars Market Outlook
 - 3.2.5.1 Broad Market Access for Growth Opportunities
 - 3.2.5.2 Compare Teva's Revenue Growth with Sandoz 2012-2022
- 3.3 Hospira
 - 3.3.1 Biosimilar Product Portfolio
 - 3.3.2 Which Biosimilar Products is Hospira Developing?
 - 3.3.2.1 Developing Biosimilars for the US Market
 - 3.3.2.2 Alliance with Celltrion for Biosimilar Monoclonal Antibodies
 - 3.3.3 Hospira: Biosimilars Market Outlook
 - 3.3.3.1 Hospira: Biosimilars SWOT Analysis 2012-2022
- 3.4 Stada Arzneimittel
 - 3.4.1 Silapo (Epoetin Zeta)
 - 3.4.2 Performance of Silapo in the EU 2008-2011
 - 3.4.3 Biosimilar Monoclonal Antibodies in Development
 - 3.4.3.1 Collaboration with Gedeon Richter 2011
 - 3.4.4 Stada: Biosimilars Market Outlook
 - 3.4.4.1 Alliances over In-House Development for Future Growth
 - 3.4.4.2 Stada: Biosimilar Revenue Forecast 2012-2022
- 3.5 Medice Arzneimittel Pütter
 - 3.5.1 Medice Markets One Biosimilar in the EU
 - 3.5.2 Medice: Biosimilars Market Outlook
- 3.6 JCR Pharmaceuticals: The Leading Japanese Market Player
 - 3.6.1 Epoetin Alfa BS Inj. JCR: Japan's Second Biosimilar
 - 3.6.2 Alliance with GSK
 - 3.6.3 Biosimilars Pipeline 2012
 - 3.6.4 JCR Pharmaceuticals: Biosimilars Market Outlook
- 3.7 New Market Entrants to Compete Strongly to 2022
 - 3.7.1 Watson Pharmaceuticals Set to Enter the Biosimilar Insulin Market
 - 3.7.2 Mylan: Another Global Generics Manufacturer Developing Biosimilars
 - 3.7.3 Big Pharma's Involvement in Biosimilars
 - 3.7.3.1 Pfizer: Exploiting Alliances and Internal Biosimilar Development for Market Entry
 - 3.7.3.2 Boehringer Ingelheim
 - 3.7.4 Local Manufacturers Looking to Enter the Japanese Market

- 3.7.4.1 Mochida Pharmaceutical
- 3.7.4.2 Nichi-Iko Pharmaceutical Partners with Sanofi for Biosimilars
- 3.7.4.3 Nippon Kayaku

4. TOP CHINESE BIOSIMILAR MANUFACTURERS 2012-2022

- 4.1 3SBio: China's Leading Biosimilars Manufacturer
 - 4.1.1 Biosimilar Product Portfolio
 - 4.1.1.1 EPAIO (Erythropoietin)
 - 4.1.2 3SBio is Dominant in the Chinese EPO Market
 - 4.1.3 Biosimilars Pipeline 2012
 - 4.1.4 3SBio: Biosimilars Market Outlook
 - 4.1.4.1 How Will Novel Drug Development Affect 3SBio's Biosimilar Performance?
 - 4.1.4.2 3SBio: Biosimilar Revenue Forecast 2012-2022
- 4.2 Beijing SL Pharmaceutical
 - 4.2.1 Specialising in Niche Biosimilars
 - 4.2.2 Biosimilar Financial Performance 2011
 - 4.2.3 Biosimilars Pipeline 2012
 - 4.2.4 Beijing SL Pharmaceutical: Biosimilars Market Outlook
 - 4.2.4.1 Targeting Monoclonal Antibodies for Future Growth
- 4.3 GeneScience Pharmaceuticals (GenSci)
 - 4.3.1 Biosimilar Product Portfolio
 - 4.3.1.1 Jintropin (Somatropin): A Low-Cost Growth Hormone
 - 4.3.2 Three Biosimilars in Development 2012
 - 4.3.3 GeneScience Pharmaceuticals: Biosimilars Market Outlook
 - 4.3.3.1 Product Launches in 2013-2014 to Drive Growth
- 4.4 Shanghai Fosun Pharmaceutical
 - 4.4.1 Shanghai Fosun's Biosimilar Insulin
 - 4.4.2 Rapid Revenue Growth 2008-2009
 - 4.4.3 Shanghai Fosun Pharmaceutical: Biosimilars Market Outlook
 - 4.4.3.1 Will Insulin Analogues Maintain Shanghai Fosun's Market Share?
- 4.5 Tonghua Dongbao
 - 4.5.1 Biosimilar Product Portfolio
 - 4.5.2 Expanding Manufacturing Capacity to Cope with Increased Demand
 - 4.5.3 Biosimilars Pipeline 2012
 - 4.5.4 Tonghua Dongbao: Biosimilars Market Outlook
 - 4.5.4.1 Tonghua Dongbao to Launch Insulin Analogues in 2015
- 4.6 The Chinese Biosimilars Market is Competitive - Many New Companies Will Enter by 2022

- 4.6.1 Can United Laboratories Gain Significant Insulin Market Share?
- 4.6.2 Shanghai CP Goujian Pharmaceutical Leads Biosimilar Monoclonal Antibody Development

5. TOP INDIAN BIOSIMILAR MANUFACTURERS 2012-2022

5.1 Biocon

5.1.1 Biosimilar Product Portfolio

5.1.1.1 Basalog: Biocon's First Insulin Analogue

5.1.2 Alliances for Entering Developed Markets

5.1.2.1 Biocon Acquires, and Sells, a Stake in AxiCorp

5.1.2.2 Pfizer: An Abandoned Biosimilar Insulin Collaboration

5.1.2.3 Biocon Partners with Mylan for Oncology Biosimilars

5.1.3 Biosimilars Pipeline 2012

5.1.4 Biocon: Biosimilars Market Outlook

5.1.4.1 Insulin and Monoclonal Antibodies: Two Key Market Sectors to Drive Growth for Biocon

5.2 Dr. Reddy's Laboratories

5.2.1 Biosimilar Product Portfolio

5.2.1.1 Reditux (Rituximab): India's First Biosimilar Monoclonal Antibody

5.2.2 Biosimilar Revenue Growth Outpaces Generic Revenue Growth 2011-2012

5.2.3 Alliance with Merck KGaA to Enter Developed Markets

5.2.4 Seven New Biosimilars to Launch by 2018

5.2.5 Dr. Reddy's Laboratories: Biosimilars Market Outlook

5.2.5.1 Opportunities Exist for Continued Biosimilar Growth 2012-2022

5.2.5.2 Dr. Reddy's Laboratories: Rapid Revenue Growth 2012-2022

5.3 Intas Biopharmaceuticals

5.3.1 Five Biosimilars Launched Since 2004

5.3.2 Filgrastim for Developed Markets: Alliance with Apotex

5.3.3 Intas Has the Longest Biosimilar Antibody Pipeline in India

5.3.4 Intas Biopharmaceuticals: Biosimilars Market Outlook

5.3.4.1 Biosimilars vs. Biobetters: Two Future Biological Drug Development Strategies

5.4 Reliance Life Sciences

5.4.1 Reliance Has Launched Seven Biosimilars in Three Years

5.4.2 Reliance GeneMedix: A Developed Market Subsidiary

5.4.3 Biosimilars Pipeline 2012

5.4.4 Reliance Life Sciences: Biosimilars Market Outlook

5.4.4.1 Can Reliance Continue its Rapid Growth in the Biosimilars Market?

5.5 Wockhardt

5.5.1 Wockhardt: Focused on Biosimilar Insulin

5.5.1.1 Wosulin

5.5.1.2 Glaritus: The World's First Biosimilar Insulin Glargine

5.5.2 Biosimilars Pipeline 2012

5.5.3 Wockhardt: Biosimilars Market Outlook

5.5.3.1 More Biosimilar Launches Expected Beyond 2015

5.6 Zydus Cadila

5.6.1 A Long History in Biosimilars

5.6.2 Twelve Biosimilars in Development 2012

5.6.3 Zydus Cadila: Biosimilars SWOT Analysis 2012-2022

5.7 More Generics Manufacturers Will Enter the Market from 2012

5.7.1 Ranbaxy Laboratories and Zenotech Laboratories Market Three Biosimilars

5.7.2 Cipla: Developing Biosimilars Since 2004

5.7.3 Lupin Pharmaceuticals

6. TOP LATIN AMERICAN BIOSIMILAR MANUFACTURERS 2012-2022

6.1 Probiomed

6.1.1 Biosimilar Products Marketed Since 1998

6.1.2 Probiomed Plans to Enter the Brazilian Market

6.1.3 Probiomed Launch Biosimilar Rituximab

6.1.4 Probiomed: Biosimilars Market Outlook

6.1.4.1 Expanding its Mature Biosimilar Portfolio to New Markets for New Opportunities 2012-2022

6.2 Biosidus

6.2.1 Two Decades of Biosimilar Market Experience

6.2.2 Facility Expansion to Meet Increased Demand 2008-2010

6.2.3 Two Biosimilars in Late-Stage Development 2012

6.2.4 Biosidus: Biosimilars Market Outlook 2012-2022

6.2.4.1 Biosidus: Biosimilars SWOT Analysis 2012-2022

6.3 Amega Biotech

6.3.1 Biosimilar Product Portfolio

6.3.2 Investment in New Manufacturing Facilities 2011-2012

6.3.3 Which New Biosimilars is Amega Biotech Developing?

6.3.4 Amega Biotech: Biosimilars Market Outlook

6.3.4.1 New Product Launches and New Markets as Growth Opportunities

6.4 Aché

6.4.1 Biosimilar Product Portfolio

6.4.2 Bionovis: Collaboration for Revenue Growth

6.4.3 Biosimilars Pipeline 2012

6.4.4 Aché: Biosimilars Market Outlook

6.4.4.1 How Will Aché's Biosimilar Portfolio Perform During This Decade?

6.5 Latin America: Emerging National Markets Providing Opportunities for New Entrants 2012-2022

7. TOP BIOSIMILAR MANUFACTURERS IN CENTRAL AND EASTERN EUROPE (CEE) AND RUSSIA 2012-2022

7.1 Bioton: Biosimilar Insulin for Emerging Markets

7.1.1 Biosimilar Product Portfolio

7.1.1.1 Gensulin

7.1.1.2 Biosimilars in Developed Markets: Biopartners

7.1.1.3 Biosimilars in Asia: SciGen

7.1.2 Insulin and Other Biosimilars: Revenue Performance 2010-2011

7.1.3 Bioton and the Chinese Insulin Market

7.1.4 Alliance with Actavis to Bring Gensulin to Developed Markets

7.1.5 Bioton: Biosimilars Market Outlook

7.1.5.1 How Will Watson's Acquisition of Actavis Impact Bioton?

7.1.5.2 Bioton: Biosimilar Revenue Forecast 2012-2022

7.2 Pharmstandard

7.2.1 Three Biosimilars Marketed in Russia

7.2.1.1 International Biotech Center (IBC) Generium

7.2.2 Above-Market Revenue Growth 2010-2011

7.2.3 Pharmstandard Has Expanded its Market Presence Through Strategic Acquisitions

7.2.4 Pharmstandard: Biosimilars Market Outlook

7.2.4.1 Pharmstandard: Biosimilars SWOT Analysis 2012-2022

7.2.4.2 Incorporation of New Subsidiaries to Drive Revenue Growth 2012-2022

7.3 CEE and Russia: Biosimilar Competitor Analysis 2012-2022

7.3.1 Gedeon Richter: Two Monoclonal Antibodies in Development

7.3.2 Egis Pharmaceuticals

8. TOP SOUTH KOREAN BIOSIMILAR MANUFACTURERS 2012-2022

8.1 LG Life Sciences: An Emerging Market Leader

8.1.1 Expertise in Fertility

8.1.2 How Have LG's Biosimilars Performed in Recent Years?

- 8.1.3 Three Biosimilar Monoclonal Antibodies in Development
- 8.1.4 LG Life Sciences: Biosimilars Market Outlook
 - 8.1.4.1 LG Life Sciences: Biosimilars SWOT Analysis 2012-2022
 - 8.1.4.2 New Product Launches for Revenue Growth 2012-2022
- 8.2 Dong-A Pharmaceutical
 - 8.2.1 Biosimilar Product Portfolio
 - 8.2.2 Revenue Growth in South Korea and Brazil 2008-2011
 - 8.2.3 Alliance with Meiji Seika Pharma to Enter the Japanese Market
 - 8.2.4 Biosimilars Pipeline 2012
 - 8.2.4.1 DA-3031 (Pegfilgrastim)
 - 8.2.5 Dong-A Pharmaceutical: Biosimilars Market Outlook
 - 8.2.5.1 Dong-A Pharmaceutical: Biosimilars SWOT Analysis 2012-2022
- 8.3 Many Companies Are Developing Biosimilar Monoclonal Antibodies in South Korea
 - 8.3.1 Celltrion: A Partner for Many Biosimilar Developers Worldwide
 - 8.3.2 Samsung Partners with Quintiles and Biogen Idec to Develop Biosimilars

9. CONCLUSIONS

- 9.1 Market Leaders 2011
- 9.2 Outlook for Market Leaders 2012-2022
- 9.3 New Competitors Entering the Market

List Of Tables

LIST OF TABLES

- Table 1.1 Currency Exchange Rates, 2011
- Table 2.1 Biosimilar Drugs Market by Sector, 2011
- Table 2.2 World Biosimilar Drugs Market: Overall Market and Sector Forecasts, 2011-2022
- Table 2.3 Top Ten Biosimilar Manufacturers, by Revenue, 2011
- Table 3.1 Leading Biosimilar Manufacturers in Developed Markets by Revenue, 2011
- Table 3.2 Sandoz: Key Facts, 2012
- Table 3.3 Sandoz: Biosimilar Revenue by Product, 2008-2011
- Table 3.4 Sandoz: Biosimilars SWOT Analysis, 2012-2022
- Table 3.5 Sandoz: Biosimilar Revenue Forecast, 2011-2022
- Table 3.6 Teva: Key Facts, 2012
- Table 3.7 Teva: Biosimilar Revenue, 2009-2011
- Table 3.8 Teva: Biosimilars SWOT Analysis, 2012-2022
- Table 3.9 Teva: Biosimilar Revenue Forecast, 2011-2022
- Table 3.10 Hospira: Key Facts, 2012
- Table 3.11 Hospira: Biosimilars SWOT Analysis, 2012-2022
- Table 3.12 Stada: Key Facts, 2012
- Table 3.13 Stada: Biosimilar Revenue, 2008-2011
- Table 3.14 Stada: Biosimilars SWOT Analysis, 2012-2022
- Table 3.15 Stada: Biosimilar Revenue Forecast, 2011-2022
- Table 3.16 Medice: Key Facts, 2012
- Table 3.17 JCR Pharmaceuticals: Key Facts, 2012
- Table 3.18 JCR Pharmaceuticals: Biosimilars SWOT Analysis, 2012-2022
- Table 3.19 Big Pharma and the Biosimilars Market, 2012
- Table 4.1 Selected Chinese Biosimilar Manufacturers and their Activities, 2012
- Table 4.2 3SBio: Key Facts, 2012
- Table 4.3 3SBio: Biosimilar Revenue by Product, 2009-2011
- Table 4.4 3SBio: Biosimilars SWOT Analysis, 2012-2022
- Table 4.5 3SBio: Biosimilar Revenue Forecast, 2011-2022
- Table 4.6 Beijing SL Pharmaceutical: Key Facts, 2012
- Table 4.7 Beijing SL Pharmaceutical: Biosimilars SWOT Analysis, 2012-2022
- Table 4.8 GeneScience Pharmaceuticals: Key Facts, 2012
- Table 4.9 GeneScience Pharmaceuticals: Biosimilars SWOT Analysis, 2012-2022
- Table 4.10 Shanghai Fosun Pharmaceutical: Key Facts, 2012
- Table 4.11 Chinese Insulin Market by Company, 2011

Table 4.12 Wanbang Biopharmaceuticals: Revenue, 2008-2009

Table 4.13 Shanghai Fosun Pharmaceutical: Biosimilars SWOT Analysis, 2012-2022

Table 4.14 Tonghua Dongbao: Key Facts, 2012

Table 4.15 Tonghua Dongbao: Biosimilars SWOT Analysis, 2012-2022

Table 5.1 Biocon: Key Facts, 2012

Table 5.2 Biocon: Biosimilars SWOT Analysis, 2012-2022

Table 5.3 Biocon: Biosimilar Discounts, 2011

Table 5.4 Dr. Reddy's Laboratories: Key Facts, 2012

Table 5.5 Dr. Reddy's Laboratories: Biosimilar Portfolio, 2012

Table 5.6 Reditux: Revenue 2008-2012

Table 5.7 Dr. Reddy's Laboratories: Biosimilar Revenue, 2011-2012

Table 5.8 Dr. Reddy's Laboratories: Biosimilars SWOT Analysis, 2012-2022

Table 5.9 Dr. Reddy's Laboratories: Biosimilar Revenue Forecast, 2011-2022

Table 5.10 Intas Biopharmaceuticals: Key Facts, 2012

Table 5.11 Intas Biopharmaceuticals: Biosimilar Product Portfolio, 2012

Table 5.12 Intas Biopharmaceuticals: Biosimilar Clinical Trials, 2012

Table 5.13 Intas Biopharmaceuticals: Biosimilars SWOT Analysis, 2012-2022

Table 5.14 Reliance Life Sciences: Key Facts, 2012

Table 5.15 Reliance Life Sciences: Biosimilar Product Portfolio, 2012

Table 5.16 Reliance Life Sciences: Biosimilars SWOT Analysis, 2012-2022

Table 5.17 Wockhardt: Key Facts, 2012

Table 5.18 Wockhardt: Biosimilars SWOT Analysis, 2012-2022

Table 5.19 Zydus Cadila: Key Facts, 2012

Table 5.20 Zydus Cadila: Biosimilar Product Portfolio, 2012

Table 5.21 Zydus Cadila: Biosimilar Pipeline, 2012

Table 5.22 Zydus Cadila: Biosimilars SWOT Analysis, 2012-2022

Table 6.1 Landsteiner Scientific: Marketed Biopharmaceuticals, 2012

Table 6.2 Probiomed: Key Facts, 2012

Table 6.3 Probiomed: Revenue, 2008-2011

Table 6.4 Probiomed: Biosimilars SWOT Analysis, 2012-2022

Table 6.5 Biosidus: Key Facts, 2012

Table 6.6 Biosidus: Biosimilars SWOT Analysis, 2012-2022

Table 6.7 Amega Biotech: R&D and Manufacturing Facilities, 2012

Table 6.8 Amega Biotech: Key Facts, 2012

Table 6.9 Amega Biotech: Revenue, 2009 & 2011

Table 6.10 Amega Biotech: Biosimilars SWOT Analysis, 2012-2022

Table 6.11 Aché: Key Facts, 2012

Table 6.12 Aché: Biosimilars SWOT Analysis, 2012-2022

Table 7.1 Bioton: Key Facts, 2012

- Table 7.2 SciGen: Revenue by Country, 2011
- Table 7.3 Bioton: Biosimilar Revenue by Company, H1 2010-2011
- Table 7.4 Bioton: Biosimilars SWOT Analysis, 2012-2022
- Table 7.5 Bioton: Biosimilar Revenue Forecast, 2011-2022
- Table 7.6 Pharmstandard: Key Facts, 2012
- Table 7.7 Pharmstandard: Insulin Manufacturing Capacity, 2010-2011
- Table 7.8 Pharmstandard: Biosimilar Revenue by Product, 2009-2011
- Table 7.9 Pharmstandard: Biosimilars SWOT Analysis, 2012-2022
- Table 7.10 Pharmstandard: Biosimilar Revenue Forecast, 2011-2022
- Table 8.1 LG Life Sciences: Key Facts, 2012
- Table 8.2 LG Life Sciences: Biosimilar Revenue by Product, 2010-2011
- Table 8.3 LG Life Sciences: Biosimilars SWOT Analysis, 2012-2022
- Table 8.4 LG Life Sciences: Biosimilar Revenue Forecast, 2011-2022
- Table 8.5 Dong-A Pharmaceutical: Key Facts, 2012
- Table 8.6 Growtropin: Revenue, 2008-2011
- Table 8.7 Dong-A Pharmaceutical: Biosimilar Export Revenue, 2009-2010
- Table 8.8 Dong-A Pharmaceutical: Biosimilars SWOT Analysis, 2012-2022
- Table 8.9 Celltrion: Biosimilar Licensing Deals, 2009-2010
- Table 9.1 Biosimilars Market Leaders: Market Shares, 2011, 2016 and 2022

List Of Figures

LIST OF FIGURES

- Figure 2.1 Biosimilar Drugs Market by Sector, 2011
- Figure 2.2 Biosimilar Drugs Market Forecast, 2011-2022
- Figure 2.3 Biosimilar Drugs Market by Sector, 2016
- Figure 2.4 Biosimilar Drugs Market by Sector, 2022
- Figure 2.5 World Biosimilar Drugs Market: Drivers and Restraints, 2012-2022
- Figure 2.6 Top Ten Biosimilar Manufacturers by Revenue, 2011
- Figure 3.1 Leading Biosimilar Manufacturers in Developed Markets by Revenue, 2011
- Figure 3.2 Sandoz: Biosimilar Revenue by Product, 2008-2011
- Figure 3.3 Sandoz: Biosimilar Revenue Forecast, 2011-2022
- Figure 3.4 Sandoz: Biosimilars Market Share, 2011, 2016 and 2022
- Figure 3.5 Teva: Biosimilar Revenue, 2009-2011
- Figure 3.6 Teva: Biosimilar Revenue Forecast, 2011-2022
- Figure 3.7 Teva: Biosimilars Market Share, 2011, 2016 and 2022
- Figure 3.8 Stada: Biosimilar Revenue, 2008-2011
- Figure 3.9 Stada: Biosimilar Revenue Forecast, 2011-2022
- Figure 3.10 Stada: Biosimilars Market Share, 2011, 2016 and 2022
- Figure 3.11 Developed Markets: Biosimilar Rituximab Development, 2012
- Figure 4.1 3SBio: Biosimilar Revenue by Product, 2009-2011
- Figure 4.2 3SBio: Biosimilar Revenue Forecast, 2011-2022
- Figure 4.3 3SBio: Biosimilars Market Share, 2011, 2016 and 2022
- Figure 4.4 Chinese Insulin Market by Company, 2011
- Figure 4.5 Wanbang Biopharmaceuticals: Revenue, 2008-2009
- Figure 5.1 Reditux: Revenue, 2008-2012
- Figure 5.2 Dr. Reddy's Laboratories: Biosimilar Revenue, 2011-2012
- Figure 5.3 Dr. Reddy's Laboratories: Biosimilar Revenue Forecast, 2011-2022
- Figure 5.4 Dr. Reddy's Laboratories: Biosimilars Market Share, 2011, 2016 and 2022
- Figure 6.1 Probiomed: Biosimilar Launches, 1998-2004
- Figure 6.2 Probiomed: Revenue, 2008-2011
- Figure 6.3 Amega Biotech: Revenue, 2009 & 2011
- Figure 7.1 SciGen: Revenue by Country, 2011
- Figure 7.2 Bioton: Biosimilar Revenue by Company, H1 2010-2011
- Figure 7.3 Bioton: Biosimilar Revenue Forecast, 2011-2022
- Figure 7.4 Bioton: Biosimilars Market Share, 2011, 2016 and 2022
- Figure 7.5 Pharmstandard: Biosimilar Revenue by Product, 2009-2011
- Figure 7.6 Pharmstandard: Biosimilar Revenue Forecast, 2011-2022

Figure 7.7 Pharmstandard: Biosimilars Market Share, 2011, 2016 and 2022
Figure 8.1 LG Life Sciences: Biosimilar Revenue by Product, 2010-2011
Figure 8.2 Biosimilar Monoclonal Antibody Progress in South Korea, 2012
Figure 8.3 LG Life Sciences: Biosimilar Revenue Forecast, 2011-2022
Figure 8.4 LG Life Sciences: Biosimilars Market Share, 2011, 2016 and 2022
Figure 8.5 Growthropin: Revenue, 2008-2011
Figure 8.6 Dong-A Pharmaceutical: Biosimilar Export Revenue, 2009-2010
Figure 9.1 Biosimilars Market Leaders: Market Shares, 2011, 2016 and 2022

COMPANIES LISTED

3SBio (Shenyang Sunshine Pharmaceutical)
Abbott Laboratories
Aché
Actavis (part of Watson)
Affitech
Amega Biotech
Amgen
Amicus Therapeutics
Anglo Gulf (part of MJ Group)
Apotex
Aprogen
ASKA Pharmaceutical
AstraZeneca
Avesthagen
AxiCorp
AzkoNobel
Baxter International
Bayer
Beijing Four Rings Bio-pharmaceutical
Beijing SL Pharmaceutical
Bigpearl Trading (part of Pharmstandard)
Bioceuticals Arzneimittel (part of Stada)
Biocon
Biogen Idec
BioGeneriX (part of Teva)
BioMab
Biomed (part of Pharmstandard)
Bionovis

Biopartners (part of Bioton)
Biopharmaceuticals and Herbal Medicines Bureau [South Korea]
Biosidus (part of Sidus Pharmaceutical Group)
Bioton
Biovel Life Sciences (part of Ranbaxy)
Blau Farmacêutica
Boehringer Ingelheim
Bristol-Myers Squibb
cell pharm (part of Stada)
Celltrion
Central Drugs Standard Control Organization (CDSCO) [India]
Chemo Group
China National Pharmaceutical Group (Sinopharm)
CinnaGen
Cipla
CJ Corporation
Clinigene International (part of Biocon)
CoGenesys (part of Teva)
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) [Mexico]
Committee for Medicinal Products for Human Use (CHMP) [EU]
CT Arzneimittel (part of Teva)
CureTech (part of Teva)
Daiichi Sankyo
Dainippon Sumitomo Pharma
DaVita
Department of Biotechnology (DBT) [India]
Diapin Therapeutics
DM Bio
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Eden Biodesign (part of Watson)
Egis Pharmaceuticals
Eli Lilly
Emcure Pharmaceuticals
EMS
Epitomics
European Medicines Agency (EMA)
Ferring Pharmaceuticals

Finox
Food and Drug Administration (FDA), [US]
Fosun International
Fresenius Medical Care
Fuji Pharma
Fujifilm
Fundação Ezequiel Dias (Funed) [Brazil]
Gan & Lee Pharmaceutical
Gedeon Richter
Genentech (part of Roche)
GeneScience Pharmaceuticals
Gennova Biopharmaceuticals (part of Emcure Pharmaceuticals)
Genzyme (part of Sanofi)
German Remedies (part of Zydus Cadila)
Germonta Holdings (part of Bioton)
Green Cross Corporation
GSK
Hangzhou Jiuyuan Gene Engineering
Hanwha Chemical
Haselmeier
Hefei-SciGen-Bioton Biopharmaceutical Company
Hemofarm (part of Stada)
Hexal (part of Novartis)
Hikma Pharmaceuticals
Hospira
Hospira Japan (part of Hospira)
Hualida Biotech
Human Genome Sciences (part of GSK)
Hypermarcas
IATRICa
Insmed
Intas Biopharmaceuticals (part of Intas Pharmaceuticals)
Intas Pharmaceuticals
International Biotech Center (IBC) Generium
Isotechnika Pharma
Isu Abxis
Itero Biopharmaceuticals
JCR Pharmaceuticals
Johnson & Johnson (J&J)

Kissei Pharmaceutical
Korea Food and Drug Administration (KFDA)
Kwizda Pharma
Kyowa Hakko Kirin
Laboratórios Biosintética (part of Aché)
Landsteiner Scientific
Lekko (part of Pharmstandard)
LG
LG Chem Investment (part of LG)
LG Life Sciences
Lonza
Lupin Pharmaceuticals
MabPharm
Marvel Life Sciences (part of MJ Group)
Masterlek (part of Pharmstandard)
Medice Arzneimittel Pütter
MedImmune (part of AstraZeneca)
Meiji Seika Pharma
Merck & Co.
Merck KGaA
Mindar Holdings (part of Bioton)
Ministry of Health [Brazil]
Ministry of Health and Family Welfare [India]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Ministry of Science and Technology [India]
MJ Biopharm (part of MJ Group)
MJ Bioton Life Sciences
MJ Group
Mochida Pharmaceutical
Mylan
NeuClone
Nichi-Iko Pharmaceutical
Nippon Kayaku
Nipro Pharma
Nobel Ilac
Norbitec
Nordmark Arzneimittel
Novartis
Novo Nordisk

Organon (part of Merck & Co.)
Owen Mumford
Parexel International
Pfenex
Pfizer
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Pharmapark (part of Pharmstandard)
Pharmstandard
Pharmstandard-Biolek (part of Pharmstandard)
Pliva (part of Teva)
Polpharma
Polpharma Biologics (part of Polpharma)
Probiomed
Prolong Pharmaceuticals
Proquifin
Qilu Pharmaceutical
Quintiles
Ranbaxy Laboratories
ratiopharm (part of Teva)
Reliance GeneMedix (part of Reliance Life Sciences)
Reliance Group
Reliance Life Sciences (part of Reliance Group)
Rentschler Biotechnologie
Roche
Royal DSM
Safety Syringes
Samsung
Samsung Bioepis
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
sanofi-aventis Nichi-Iko
Savient Pharmaceuticals (part of Ferring)
Schering-Plough (part of Merck & Co.)
Schnell Biopharmaceuticals
SciGen
Shandong Kexing Bioproducts
Shanghai Celgen Bio-Pharmaceutical
Shanghai Chemo Wanbang Biopharma

Shanghai CP Goujian Pharmaceutical
Shanghai Fosun Pharmaceutical
Shanghai Henlius Biotech
Shantha Biotechnics (part of Sanofi)
Sicor Biotech (part of Teva)
Sidus Pharmaceutical Group
Silanes
Stada Arzneimittel
State Food and Drug Administration (SFDA) [China]
State's Employees' Social Security and Social Services Institute (ISSSTE) [Mexico]
Sundiro Pharma
Syngene (part of Biocon)
Teva Pharmaceutical Industries
Teva-Kowa Pharma (part of Teva)
The United Laboratories
Therapeutic Goods Administration (TGA) [Australia]
TL Biopharmaceutical
Tonghua Dongbao
União Química
University of Michigan
Wanbang Biopharmaceuticals (part of Shanghai Fosun Pharmaceuticals)
Watson Pharmaceuticals
Wockhardt
World Health Organization (WHO)
Xiamen Amoytop Biotech
Ypsomed
Zao Indar
Zenotech Laboratories
Zuventus Healthcare (part of Emcure Pharmaceuticals)
Zydus Cadila

I would like to order

Product name: Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022

Product link: <https://marketpublishers.com/r/P57CA921E30EN.html>

Price: US\$ 2,401.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P57CA921E30EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970